NLPHL
MCID: NDL021
MIFTS: 44

Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) malady

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Aliases & Descriptions for Nodular Lymphocyte Predominant Hodgkin Lymphoma:

Name: Nodular Lymphocyte Predominant Hodgkin Lymphoma 56 69
Nlphl 56

Characteristics:

Orphanet epidemiological data:

56
nodular lymphocyte predominant hodgkin lymphoma
Prevalence: 1-9/1000000 (Worldwide),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Orphanet 56 ORPHA86893
UMLS via Orphanet 70 C1334968 C2239290
ICD10 via Orphanet 34 C81.0
ICD10 33 C81.0

Summaries for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards based summary : Nodular Lymphocyte Predominant Hodgkin Lymphoma, also known as nlphl, is related to hodgkin lymphoma and lymphoma, and has symptoms including hyperhidrosis, pruritus and splenomegaly. An important gene associated with Nodular Lymphocyte Predominant Hodgkin Lymphoma is PAX5 (Paired Box 5), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and TNFR1 Pathway. The drugs Vinblastine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone marrow, and related phenotypes are cellular and hematopoietic system

Related Diseases for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
id Related Disease Score Top Affiliating Genes
1 hodgkin lymphoma 11.4
2 lymphoma 10.9
3 b-cell lymphomas 10.5
4 hodgkin's granuloma 10.5
5 t-cell/histiocyte rich large b cell lymphoma 10.3
6 diffuse large b-cell lymphoma 10.3
7 subacute delirium 10.1 PAX5 PTPRC
8 ureter transitional cell carcinoma 10.1 PAX5 REL
9 embryonal testis carcinoma 10.1 PDCD1 PTPRC
10 ureter small cell carcinoma 10.1 PAX5 REL
11 neurofibromatosis 10.1 PAX5 PTPRC
12 lip cancer 10.1 PAX5 PTPRC
13 cortical blindness 10.0 PTPRC VIM
14 developmental coordination disorder 10.0 PTPRC VIM
15 ribbing disease 10.0 PTPRC VIM
16 peripheral t-cell lymphoma 10.0
17 appendix mucinous cystadenocarcinoma 10.0 PTPRC VIM
18 omodysplasia 2 10.0 PTPRC VIM
19 congenital muscular dystrophy with hyperlaxity 10.0 PTPRC VIM
20 ectodermal dysplasia 10.0 PAX5 REL
21 lung benign neoplasm 10.0 PTPRC VIM
22 desmoid tumor 10.0 PTPRC VIM
23 kidney benign neoplasm 10.0 PTPRC VIM
24 aortic arch interruption 10.0 PAX5 PTPRC
25 diabetes persistent mullerian ducts 9.9 PTPRC VIM
26 carnitine-acylcarnitine translocase deficiency 9.9 PAX5 PTPRC REL
27 preretinal fibrosis 9.9 PTPRC VIM
28 kaposi sarcoma 9.9
29 warthin tumor 9.9
30 hemolytic anemia 9.9
31 hepatitis 9.9
32 sarcoma 9.9
33 leiomyoma 9.9
34 cervicitis 9.9
35 polyradiculopathy 9.9
36 adult lymphoma 9.9
37 thyroiditis 9.9
38 autoimmune hemolytic anemia 9.9
39 progressive transformation of germinal centers 9.9
40 chronic venous leg ulcers 9.6 NFKBIA PAX5 PTPRC
41 hinman syndrome 9.2 NFKBIA PAX5 PDCD1 PTPRC REL VIM

Graphical network of the top 20 diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:



Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma

Symptoms & Phenotypes for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Human phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

56 32 (show all 14)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 56 32 Occasional (29-5%) HP:0000975
2 pruritus 56 32 Occasional (29-5%) HP:0000989
3 splenomegaly 56 32 Occasional (29-5%) HP:0001744
4 weight loss 56 32 Occasional (29-5%) HP:0001824
5 fever 56 32 Frequent (79-30%) HP:0001945
6 anorexia 56 32 Occasional (29-5%) HP:0002039
7 hepatomegaly 56 32 Occasional (29-5%) HP:0002240
8 lymphadenopathy 56 32 Very frequent (99-80%) HP:0002716
9 immunodeficiency 56 32 Very frequent (99-80%) HP:0002721
10 breast carcinoma 56 32 Occasional (29-5%) HP:0003002
11 abnormality of bone marrow cell morphology 56 32 Occasional (29-5%) HP:0005561
12 b-cell lymphoma 56 32 Occasional (29-5%) HP:0012191
13 fatigue 56 32 Occasional (29-5%) HP:0012378
14 lymphoma 56 Very frequent (99-80%)

MGI Mouse Phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 PDCD1 PTPRC REL VIM NFKBIA PAX5
2 hematopoietic system MP:0005397 9.8 PTPRC REL VIM NFKBIA PAX5 PDCD1
3 immune system MP:0005387 9.73 PTPRC REL VIM NFKBIA PAX5 PDCD1
4 mortality/aging MP:0010768 9.63 PDCD1 PTPRC REL VIM NFKBIA PAX5
5 nervous system MP:0003631 9.35 PDCD1 PTPRC REL VIM PAX5
6 respiratory system MP:0005388 8.92 PDCD1 PTPRC REL VIM

Drugs & Therapeutics for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Drugs for Nodular Lymphocyte Predominant Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 4,Phase 3,Phase 2 865-21-4 13342 241903
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
6 Prednisolone acetate Phase 4,Phase 3,Phase 2
7 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
8 glucocorticoids Phase 4,Phase 3,Phase 2
9 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
10 Neuroprotective Agents Phase 4,Phase 3,Phase 2
11 Hormone Antagonists Phase 4,Phase 3,Phase 2
12 Hormones Phase 4,Phase 3,Phase 2
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
15 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2
16 Prednisolone phosphate Phase 4,Phase 3,Phase 2
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Protective Agents Phase 4,Phase 3,Phase 2
19 Antiemetics Phase 4,Phase 3,Phase 2
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
21 Methylprednisolone acetate Phase 4,Phase 3,Phase 2
22 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2
23 Antimitotic Agents Phase 4,Phase 3,Phase 2
24 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
26 Autonomic Agents Phase 4,Phase 3,Phase 2
27 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
28 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2
29
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
30
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
31
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
32
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
33
Bleomycin Approved Phase 3,Phase 2 11056-06-7 5360373
34
Procarbazine Approved Phase 3,Phase 2 671-16-9 4915
35
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
36
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
37
Lenograstim Approved Phase 3,Phase 2 135968-09-1
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
39
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
40
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
41
Succinylcholine Approved Phase 3 306-40-1 5314
42
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
43
Cortisone acetate Approved Phase 3 1950-04-4, 50-04-4 5745
44
Doxil Approved June 1999 Phase 3,Phase 2 31703
45 Adjuvants, Immunologic Phase 3,Phase 2
46 Topoisomerase Inhibitors Phase 3,Phase 2
47 Anti-Bacterial Agents Phase 3,Phase 2
48 Etoposide phosphate Phase 3,Phase 2
49 Fluorodeoxyglucose F18 Phase 3,Phase 2
50 Antibiotics, Antitubercular Phase 3,Phase 2

Interventional clinical trials:

(show all 32)
id Name Status NCT ID Phase
1 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Recruiting NCT01088750 Phase 4
2 Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma Unknown status NCT00678327 Phase 3
3 Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma Unknown status NCT00041210 Phase 3
4 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3
5 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3
6 Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease Completed NCT00002561 Phase 3
7 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Active, not recruiting NCT00003389 Phase 3
8 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00002461 Phase 2
9 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma Unknown status NCT00002715 Phase 2
10 Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Completed NCT01187303 Phase 2
11 Rituximab in Treating Patients With Hodgkin's Lymphoma Completed NCT00003820 Phase 2
12 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed NCT01460940 Phase 2
13 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy Completed NCT00381940 Phase 2
14 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed NCT00132028 Phase 2
15 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. Completed NCT01022996 Phase 2
16 SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed NCT00337194 Phase 2
17 Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00006760 Phase 2
18 Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma Completed NCT00070304 Phase 2
19 Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma Completed NCT00666484 Phase 2
20 Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease Completed NCT00004010 Phase 2
21 Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) Recruiting NCT02626884 Phase 2
22 Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma Recruiting NCT01118026 Phase 2
23 Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Active, not recruiting NCT01535924 Phase 1, Phase 2
24 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Active, not recruiting NCT01476410 Phase 2
25 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Active, not recruiting NCT00822120 Phase 2
26 Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Terminated NCT00288067 Phase 1, Phase 2
27 Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Terminated NCT00112723 Phase 1, Phase 2
28 Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment Withdrawn NCT00881387 Phase 2
29 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1
30 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Recruiting NCT02168140 Phase 1
31 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
32 Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma Completed NCT01366157

Search NIH Clinical Center for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Genetic Tests for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Anatomical Context for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards organs/tissues related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

39
B Cells, T Cells, Bone Marrow, Bone, Breast, Lymph Node, Monocytes

Publications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Articles related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

(show top 50) (show all 134)
id Title Authors Year
1
Cyclin D1 expression and polysomy in lymphocyte-predominant cells of nodular lymphocyte-predominant Hodgkin lymphoma. ( 28038705 )
2017
2
Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 28522441 )
2017
3
Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. ( 27998726 )
2017
4
An unusual clinical and pathological presentation of a nodular lymphocyte predominant Hodgkin lymphoma ("Poppema Lennert" lymphoma). ( 27532537 )
2016
5
Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 27999289 )
2016
6
A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma. ( 27708232 )
2016
7
Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. ( 26658840 )
2016
8
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma. ( 26913966 )
2016
9
Nodular lymphocyte-predominant Hodgkin lymphoma. ( 27496311 )
2016
10
A case of composite classical and nodular lymphocyte predominant Hodgkin lymphoma with progression to diffuse large B-cell non-Hodgkin lymphoma: Diagnostic difficulty in fine-needle aspiration cytology. ( 27888658 )
2016
11
The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children. ( 26872637 )
2016
12
Nodular Lymphocyte Predominant Hodgkin Lymphoma Presenting with Unilateral Orbital Involvement. ( 27015240 )
2016
13
Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. ( 26762971 )
2016
14
Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group. ( 26996288 )
2016
15
Diagnostic Utility of Flow Cytometry Analysis of Reactive T Cells in Nodular Lymphocyte-Predominant Hodgkin Lymphoma. ( 26712878 )
2016
16
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. ( 26837698 )
2016
17
A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. ( 26732883 )
2016
18
Atypical variants of nodular lymphocyte predominant Hodgkin lymphoma show low microvessel density and vessels of distention type. ( 27816718 )
2016
19
Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Thyroid. ( 28044111 )
2016
20
Primary nodular lymphocyte-predominant Hodgkin lymphoma of uterine cervix mimicking leiomyoma. ( 26185626 )
2015
21
Nodular lymphocyte predominant Hodgkin lymphoma: Clincopathological study of 25 cases from Japan with a reappraisal of tissue associated macrophages. ( 26538151 )
2015
22
Characteristics and outcomes of patients with nodular lymphocyte-predominant hodgkin lymphoma versus those with classical hodgkin lymphoma: a population-based analysis. ( 25863756 )
2015
23
CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma. ( 26380151 )
2015
24
Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations. ( 25929348 )
2015
25
Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. ( 26685097 )
2015
26
Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. ( 26538004 )
2015
27
XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma. ( 26062064 )
2015
28
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. ( 26430172 )
2015
29
Management of nodular lymphocyte predominant hodgkin lymphoma in the modern era. ( 25863755 )
2015
30
Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - A review of clinical outcome based on the histological variants. ( 26115355 )
2015
31
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. ( 26240235 )
2015
32
Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. ( 26356319 )
2015
33
Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications. ( 25487651 )
2015
34
Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma. ( 26410017 )
2015
35
Lymphocyte-Rich Classical Hodgkin Lymphoma. A Case with Difficulty in Distinguishing from Nodular Lymphocyte-Predominant Hodgkin Lymphoma. ( 26106003 )
2015
36
Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma. ( 26149195 )
2015
37
Incidence, management and outcome of high grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience. ( 25715900 )
2015
38
What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma? ( 26022927 )
2015
39
High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma. ( 26467917 )
2015
40
Nodular Lymphocyte-Predominant Hodgkin Lymphoma in a Warthin Tumor of the Parotid Gland: A Case Report and Literature Review. ( 26169920 )
2015
41
Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. ( 26585412 )
2015
42
Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base. ( 26149294 )
2015
43
Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival. ( 26110882 )
2015
44
Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. ( 25644177 )
2015
45
Intrafollicular classical Hodgkin lymphoma mimicking nodular lymphocyte predominant Hodgkin lymphoma: A report of two cases. ( 25394195 )
2014
46
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. ( 24516013 )
2014
47
Fluorescence immunophenotyping and interphase cytogenetics (FICTION) detects BCL6 abnormalities, including gene amplification, in most cases of nodular lymphocyte-predominant Hodgkin lymphoma. ( 24678684 )
2014
48
Primary adrenal nodular lymphocyte-predominant Hodgkin lymphoma: A case report and review of the literature. ( 25120675 )
2014
49
Open questions in the management of nodular lymphocyte predominant hodgkin lymphoma. ( 24772357 )
2014
50
A simplified scoring system to document variant patterns in nodular lymphocyte predominant Hodgkin lymphoma. ( 25248885 )
2014

Variations for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Expression for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Search GEO for disease gene expression data for Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Pathways for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Pathways related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 25)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 NFKBIA PDCD1 PTPRC REL
2
Show member pathways
12.55 NFKBIA PTPRC REL
3
Show member pathways
12.28 NFKBIA PTPRC REL
4
Show member pathways
12.18 NFKBIA PTPRC REL
5
Show member pathways
11.92 NFKBIA PTPRC REL
6 11.85 NFKBIA PAX5 PDCD1 PTPRC REL
7
Show member pathways
11.83 NFKBIA PTPRC REL
8
Show member pathways
11.66 PDCD1 PTPRC
9
Show member pathways
11.58 NFKBIA REL
10
Show member pathways
11.57 NFKBIA REL
11
Show member pathways
11.45 NFKBIA REL
12 11.43 NFKBIA REL
13
Show member pathways
11.43 NFKBIA PDCD1 PTPRC REL VIM
14 11.41 PAX5 PDCD1
15
Show member pathways
11.36 NFKBIA REL
16 11.28 PTPRC REL
17
Show member pathways
11.26 NFKBIA REL
18 11.24 NFKBIA REL
19
Show member pathways
11.19 NFKBIA REL
20 11.1 NFKBIA REL
21 11.06 PAX5 PDCD1 PTPRC
22 11.05 NFKBIA REL
23
Show member pathways
10.92 NFKBIA REL
24 10.9 NFKBIA PDCD1
25 10.4 NFKBIA REL

GO Terms for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Cellular components related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 I-kappaB/NF-kappaB complex GO:0033256 8.62 NFKBIA REL

Biological processes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 I-kappaB kinase/NF-kappaB signaling GO:0007249 8.96 NFKBIA REL
2 humoral immune response GO:0006959 8.62 PAX5 PDCD1

Sources for Nodular Lymphocyte Predominant Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....